Delaware.gov logo
Division of Small Business

Prelude Therapeutics raises $60 million in new funding round


Prelude Therapeutics, a Wilmington-based, clinical-stage pharmaceutical company, raised $60 million in a recently closed Series B funding round, the company announced.

The $60 million raised brings to $90 million the amount the company has raised to date, Prelude Therapeutics said in a press release.

Prelude Therapeutics develops small molecule drugs that target the growth of cancer cells.

The company received a $474,491 Delaware Strategic Fund grant in 2017.

Prelude’s founder and CEO, Dr. Kris Vaddi, was part of the founding team at Wilmington-based Incyte Corp.

Click here to read the Prelude Therapeutics press release.

The Delaware Division of Small Business wants to help you start or grow your business in Delaware.

Contact us to see how we can help you.


Related Topics:  , ,



business@delaware.gov

CONNECT:   Division of Small Business Facebook Page  |  Division of Small Business Twitter Feed

+